Cash proceeds, along with fair value disclosures related to grants, exercises, and vesting options (Details) - USD ($) $ / shares in Units, $ in Thousands |
12 Months Ended | ||||
|---|---|---|---|---|---|
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|||
| Share-Based Payment Arrangement [Abstract] | |||||
| Proceeds from stock options exercised | $ 0 | $ 132 | $ 0 | ||
| Intrinsic value of stock options exercised | [1] | $ 0 | $ 82 | $ 0 | |
| Weighted-average fair value of options granted per share | $ 0 | $ 0.66 | $ 0.29 | ||
| Total fair value of shares vested during the year | $ 42 | $ 404 | $ 227 | ||
| |||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of cash inflow from exercise of option under share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|